SCS wins media patent
Thursday, 10 July, 2008
Stem Cell Sciences [ASX: STC] has been granted a UK Patent Office patent for the company's new range of stem cell culture media.
The patent covers the company's Culticell iSTEM range, which contains a combination of enzyme inhibitors. The range is based on technology described in Nature recently by stem cell research pioneer Professor Austin Smith, now at Cambridge University, who is chair of the company's scientific advisory board.
Smith discovered that with the inhibition of key enzymes in specific combinations it is possible to produce pluripotent stem cells without feeder cells, growth factors, leukaemia inhibitory factor or serum.
The patent covers every use of the media, including use of the media for cultivating stem cells.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
